- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06041386
REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study (REIMAGINE)
A Prospective, Real-World, Interventional Study To Evaluate The Effect Of Mepolizumab On Achieving Clinical Remission In Participants With Severe Asthma
This is a prospective, real-world, single arm, global, multi-centre study to evaluate the effect of timely treatment with mepolizumab (NUCALA) to achieve clinical remission in adult participants with severe asthma with an eosinophilic phenotype (SA-EP).
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Kortrijk, Belgium, 8500
- GSK Investigational Site
-
Liège, Belgium, 4000
- GSK Investigational Site
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T3B0M3
- GSK Investigational Site
-
Calgary, Alberta, Canada
- GSK Investigational Site
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3L 1Z5
- GSK Investigational Site
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1E2
- GSK Investigational Site
-
-
-
-
-
Brest, France, 29200
- GSK Investigational Site
-
Cannes, France, 06614
- GSK Investigational Site
-
Lille, France, 59000
- GSK Investigational Site
-
Lyon, France, 69004
- GSK Investigational Site
-
Strasbourg, France, 67091
- GSK Investigational Site
-
Toulouse, France, 31059
- GSK Investigational Site
-
-
-
-
-
Bonn, Germany, 53119
- GSK Investigational Site
-
Hohenstein-Ernsttal, Germany, 9337
- GSK Investigational Site
-
Schleswig, Germany, 53123
- GSK Investigational Site
-
-
Hesse
-
Darmstadt, Hesse, Germany, 64283
- GSK Investigational Site
-
Frankfurt am Main, Hesse, Germany, 60389
- GSK Investigational Site
-
-
North Rhine-Westphalia
-
Aachen, North Rhine-Westphalia, Germany, 52074
- GSK Investigational Site
-
-
-
-
-
Genova, Italy, 16132
- GSK Investigational Site
-
Monserrato CA, Italy, 09042
- GSK Investigational Site
-
Naples, Italy, 80131
- GSK Investigational Site
-
Pieve Di Soligo TV, Italy, 131044
- GSK Investigational Site
-
Roma, Italy, 00128
- GSK Investigational Site
-
Roma, Italy, 161
- GSK Investigational Site
-
Rozzano, Italy, 20089
- GSK Investigational Site
-
Verona, Italy, 37126
- GSK Investigational Site
-
-
-
-
-
Gifu, Japan, 509-6134
- GSK Investigational Site
-
Kagawa, Japan, 760-0018
- GSK Investigational Site
-
Tokyo, Japan, 142-8666
- GSK Investigational Site
-
Tokyo, Japan, 173-8606
- GSK Investigational Site
-
Tokyo, Japan, 105-0003
- GSK Investigational Site
-
-
-
-
-
?Od?, Poland, 90-153
- GSK Investigational Site
-
Gdansk, Poland, 80-214
- GSK Investigational Site
-
Lodz, Poland, 92-213
- GSK Investigational Site
-
-
-
-
-
Barcelona, Spain, 08025
- GSK Investigational Site
-
Girona, Spain, 17005
- GSK Investigational Site
-
Valencia, Spain, 46015
- GSK Investigational Site
-
-
-
-
California
-
La Jolla, California, United States, 92037
- GSK Investigational Site
-
Newport Beach, California, United States, 92663
- GSK Investigational Site
-
-
Colorado
-
Aurora, Colorado, United States, 71105
- GSK Investigational Site
-
Colorado Springs, Colorado, United States, 80923
- GSK Investigational Site
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- GSK Investigational Site
-
-
Florida
-
Homestead, Florida, United States, 33032-8185
- GSK Investigational Site
-
Jacksonville, Florida, United States, 32209
- GSK Investigational Site
-
Miami, Florida, United States, 33125
- GSK Investigational Site
-
Plantation, Florida, United States, 33317
- GSK Investigational Site
-
-
Georgia
-
Adairsville, Georgia, United States, 30103
- GSK Investigational Site
-
Columbus, Georgia, United States, 31904
- GSK Investigational Site
-
-
Kentucky
-
Lexington, Kentucky, United States, 40509-1801
- GSK Investigational Site
-
Owensboro, Kentucky, United States, 42301
- GSK Investigational Site
-
-
Louisiana
-
New Orleans, Louisiana, United States, 34452
- GSK Investigational Site
-
-
Maryland
-
Glenn Dale, Maryland, United States, 20769
- GSK Investigational Site
-
Towson, Maryland, United States, 21204
- GSK Investigational Site
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48103
- GSK Investigational Site
-
-
Minnesota
-
Linwood, Minnesota, United States, 55092
- GSK Investigational Site
-
Rochester, Minnesota, United States, 55905-0001
- GSK Investigational Site
-
-
Nevada
-
Henderson, Nevada, United States, 89052-5015
- GSK Investigational Site
-
-
New York
-
Rochester, New York, United States, 14607
- GSK Investigational Site
-
Schenectady, New York, United States, 12308
- GSK Investigational Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19140
- GSK Investigational Site
-
Philadelphia, Pennsylvania, United States, 19141
- GSK Investigational Site
-
-
South Carolina
-
Union, South Carolina, United States, 29379-7409
- GSK Investigational Site
-
-
Texas
-
Cypress, Texas, United States, 77429-1439
- GSK Investigational Site
-
Kerrville, Texas, United States, 78028
- GSK Investigational Site
-
McKinney, Texas, United States, 75069
- GSK Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participant has a confirmed asthma diagnosis and has been prescribed NUCALA by their physician for the treatment of asthma, as per local label. NUCALA can be initiated up to 7 days prior to study enrollment.
- No NUCALA use in the 6 months prior to enrollment.
- Participants with greater than or equal to (≥)60 percentage (%) predicted forced expiratory volume in 1 second (FEV1) and less than or equal to (≤)4 exacerbations per year, as confirmed by the physician.
- Other local prescription criteria of NUCALA not described above at NUCALA initiation (e.g., local reimbursement criteria).
- Written informed consent
Exclusion Criteria:
- Investigator concerns about participant's willingness to adhere to biologic treatment for any reason (e.g., cost, behavior, difficulty with access to healthcare)
- Participants currently on maintenance OCS or intramuscular corticosteroids.
- Participants using omalizumab, reslizumab, dupilumab, tezepelumab, or benralizumab within the 6 months prior to enrollment
- Participants participating in an interventional study with a treatment intervention
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Group 1
Participants with a clinical diagnosis of Severe asthma prescribed Mepolizumab as part of routine care. |
Mepolizumab will be prescribed based on physician decision. Lung function via spirometry will be collected. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage (%) of Participants Achieving 4-Component Clinical Remission
Time Frame: At month 12
|
4-component clinical remission is defined as (a) No clinically significant asthma exacerbations (b) No OCS use for asthma (c) Well controlled asthma based on an Asthma Control Test (ACT) (d) No clinically significant deterioration of lung function. |
At month 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Annualized Rates of Clinically Significant Asthma Exacerbations (CSE) and CSE Leading to Hospitalization/ Emergency Room (ER) Visits
Time Frame: At month 12
|
CSE is defined as a deterioration in asthma requiring (1) the initiation of systemic corticosteroids and/or (2) an ER visit and/or hospital admission. |
At month 12
|
|
Percentage of Participants Achieving OCS Sparing Remission
Time Frame: At month 12
|
OCS sparing is defined as (a) No clinically significant asthma exacerbations during the period of interest (b) No OCS use for asthma at the time point of interest. |
At month 12
|
|
Percentage of Participants Achieving 3-Component Clinical Remission
Time Frame: At month 12
|
3-component clinical remission is defined as (a) No clinically significant asthma exacerbations (b) No OCS use for asthma (c) Well controlled asthma based on an ACT |
At month 12
|
|
Mean Change from Baseline in Mini-Asthma Quality of Life Questionnaire (AQLQ) Overall Score
Time Frame: Baseline and at month 12
|
The mini-AQLQ overall score is a reduced version of the AQLQ which includes 15 items. The minimally clinically important difference (MCID) is 0.5. The response options for each item are on an equidistant scale of 7 points, where 1 corresponds to the maximum disability and 7 to the absence of disability |
Baseline and at month 12
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: GSK Clinical Trials, GlaxoSmithKline
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 219871
- 2023 (U.S. NIH Grant/Contract)
- 2023-509026-21-00 (Registry Identifier: CTIS (EU))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/
IPD Sharing Time Frame
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
IPD Sharing Access Criteria
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.